Premier Alternatives

Sonaro

Montreal, Canada · Privately Held (backing)

Developer of an ultrasound diagnostic artificial intelligence-based technology designed to predict the risk of thromboembolic events. Sonaro is based in Montreal, Canada. Its last reported valuation was $4.4 million in Dec 2024. It has raised $140,000.

Last reported valuation
$4.4M
Oct 2026
Priced at
—
Total raised
$140K
Last round
—

Sonaro key facts

as of Oct 2026
  • Developer of an ultrasound diagnostic artificial intelligence-based technology designed to predict the risk of thromboembolic events.
  • Sonaro is valued at approximately $4.4M as of Oct 2026 (last reported valuation).
  • It has raised $140K; the latest was Angel (individual) in Apr 2026.
  • Notable investors include Creative Destruction Lab, University of Toronto Entrepreneurship, Centech Accelerator, Front Row Ventures, Québec Tech — 21 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$4.4M

Sonaro's last reported valuation, Dec 2024. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Sonaro with a free account
  • ·The complete investor list: 21 names
  • ·Watch Sonaro: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Sonaro funding rounds

No rounds on record

No funding rounds for Sonaro are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Sonaro valuation

Sonaro's last reported valuation was $4.4 million in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.

Sonaro investors

21 investors are on record for Sonaro, including Creative Destruction Lab, University of Toronto Entrepreneurship, Centech Accelerator and Front Row Ventures.

About Sonaro

Developer of an ultrasound diagnostic artificial intelligence-based technology designed to predict the risk of thromboembolic events. The company's AI-powered offer a flagship product that converts traditional two-dminsional ultrasound data into accurate three-dimensional models of the carotid arteries and improves stroke risk assessment by diagnostic accuracy, reducing operator workload, and delivering results in minutes, making diagnostic ultrasound for vascular diseases accessible to every individual, enabling clinicians to obtain detailed clinical reports on vascular characteristics like volume and the presence of high-risk features.

Sector
Healthcare
HQ
Montreal, Canada
Employees
6
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.